Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity
Dr. Keith Vossel, Professor of Neurology and Director of the UCLA Easton Center, published the highly anticipated results of a phase 2a randomized, placebo-controlled clinical trial of the anti-seizure medication levetiracetam for Alzheimer’s disease. This study was published in JAMA Neurology. The clinical trial showed that levetiracetam improves cognitive functions in Alzheimer’s patients with epileptic activity. The publication was featured in UCLA Health News and other news resources such as Newswise, Science Daily, News Medical, and more.
Related Articles
UCLA Develops New Alzheimer's Disease Therapeutic
Dr. Varghese John, Dr. Istvan Mody, and colleagues were highlighted in a UCLA article about their recent therapeutic development, targeting ...
Healthy Body. Healthy Mind.
In the Summer Edition of Keiro Connect, Dr. Kevin Bickart discussed physical activity, including dancing, to improve brain health and prevent dementia ...
A More Inclusive Framework for Alzheimer’s Disease
The Easton Center, ELHA Lab, UCLA Neurology, Alzheimer's Los Angeles, and community leaders are working together bridging the gap between health disparities ...
An In-Depth Interview on Various Neurodegenerative Diseases
Dr. Keith Vossel was interviewed by Dr. Marc Siegel from Doctor Radio/Sirius XM about a wide spectrum of neurodegenerative diseases, including ...